Company news

Beyond Air, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Beyond Air® Reports Financial Results for Fourth Fiscal Quarter and Year-End 2022

June 27, 2022

Beyond Air® Announces Fiscal Year End 2022 Financial Results Conference Call and Webcast Moved to Tuesday, June 28th

June 13, 2022

Beyond Cancer™ Announces the Appointment of Jedidiah Monson, M.D. to Chief Medical Officer

May 31, 2022

Beyond Air® Presents Positive Study Update from the At-Home LungFit® GO Pilot Study for Nontuberculous Mycobacterial Lung Disease at the American Thoracic Society International Conference 2022

May 16, 2022

Beyond Air® Schedules Fiscal Year 2022 Financial Results Conference Call and Webcast

May 15, 2022

Beyond Air® Reports Positive Long-Term Safety Data for High Concentration Inhaled Nitric Oxide in Bronchiolitis at the Pediatric Academic Societies Meeting 2022

April 24, 2022

Beyond Cancer™ Announces New Preclinical Data Presented at American Association for Cancer Research (AACR) Showing Ultra-High Concentration Nitric Oxide Therapy Anti-Tumor Effect

April 10, 2022

Beyond Air® Reports Financial Results for the Third Quarter of Fiscal Year 2022

February 9, 2022

Beyond Air® Announces Participation at Upcoming Investor Conferences in March 2022

February 7, 2022

Beyond Air® Announces Two Appointments to Beyond Cancer™ Board of Directors

February 2, 2022

Beyond Air® Schedules Third Fiscal Quarter 2022 Financial Results Conference Call and Webcast

January 26, 2022

Beyond Air® Provides Regulatory Update for LungFit® PH

December 8, 2021

Beyond Air® Expands Leadership Team with the Appointment of Dr. Andrew Colin to Chief Medical Officer

November 30, 2021

Beyond Air® Announces $30 Million of Committed Capital in Previously Reported Beyond Cancer™ Private Placement

November 17, 2021

Beyond Air® Reports Financial Results for the Second Quarter of Fiscal Year 2022

November 10, 2021

Beyond Air® Announces Formation of Beyond Cancer™, a New Private Company Dedicated to Oncology Utilizing Ultra-High Concentration Nitric Oxide to Treat Solid Tumors

November 3, 2021

Beyond Air® Schedules Second Fiscal Quarter 2022 Financial Results Conference Call and Webcast

October 24, 2021

Beyond Air® Reports Positive Interim Results for LungFit® GO Pilot Study Using High Concentration Inhaled Nitric Oxide Self-Administered, At-Home for Nontuberculous Mycobacterial Lung Disease

October 19, 2021

Beyond Air® Provides Global Regulatory Update for LungFit® PH

September 20, 2021

Beyond Air® Announces CFO Transition

August 19, 2021

Beyond Air® Reports Financial Results for the First Quarter of Fiscal Year 2022

August 9, 2021

Beyond Air® Schedules First Fiscal Quarter 2022 Financial Results Conference Call and Webcast

July 19, 2021

Beyond Air® Announces Participation at Upcoming Virtual Investor Conferences in July 2021

July 7, 2021

Beyond Air® Reports Financial Results for Fourth Fiscal Quarter and Year-End 2021

June 9, 2021

Beyond Air® Reaches Settlement Agreement with Circassia for LungFit® PH

May 25, 2021

Beyond Air® Schedules Fiscal Year 2021 Financial Results Conference Call and Webcast

May 24, 2021

Beyond Air® Strengthens Commercial Leadership Team with Appointments of Head of Sales and Head of Marketing

May 19, 2021

Beyond Air® Presents Data in Hospitalized Patients with Viral Lung Infections (including COVID-19) from LungFit® PRO Programs at ATS 2021

May 12, 2021

Beyond Air® Appoints Peter Senior as Director of Business Development

May 2, 2021

Beyond Air® Announces Participation at Upcoming Virtual Investor Conferences in May 2021

April 13, 2021

Beyond Air® to Present Abstracts at the American Thoracic Society Virtual Sessions in May 2021

March 23, 2021

Beyond Air® Announces Participation at Upcoming Virtual Investor Conferences in March 2021

February 28, 2021

Beyond Air® Receives Grant for Up to $2.17 million from the Cystic Fibrosis Foundation to Advance the Clinical Development of Inhaled Nitric Oxide to Treat Nontuberculous Mycobacteria Pulmonary Disease

February 15, 2021

Beyond Air® Reports Financial Results for Third Quarter of Fiscal Year 2021 and Provides Business Update

February 8, 2021

Beyond Air® Schedules Third Fiscal Quarter 2021 Financial Results Conference Call and Webcast

January 14, 2021

Beyond Air® Initiates Patient Screening for LungFit™ GO Pilot Study for At-Home, Self-Administration of Inhaled Nitric Oxide in Nontuberculous Mycobacteria Lung Disease

December 6, 2020

Beyond Air® Submits Premarket Approval Application to FDA for LungFit™ PH to Treat Persistent Pulmonary Hypertension of the Newborn

November 10, 2020

Beyond Air® Reports Financial Results for Second Quarter of Fiscal Year 2021 and Provides Business Update

November 10, 2020

Beyond Air® Schedules Second Fiscal Quarter 2021 Financial Results Conference Call and Webcast

October 22, 2020

Beyond Air® Approved to Initiate Clinical Study at 150 ppm Nitric Oxide with LungFit™ for the Treatment of Acute Viral Pneumonia Including COVID-19

October 20, 2020

Beyond Air® Presents Data Showing Anti-Coronavirus Activity of Nitric Oxide at the CHEST Annual Meeting 2020

October 18, 2020

Beyond Air® Presents Positive New Preclinical Data for the Use of a Single Injection of Gaseous Nitric Oxide as a Novel In situ Cancer Vaccination

October 15, 2020

Beyond Air® to Present Data on Nitric Oxide in the Treatment of Solid Tumors at the American Association for Cancer Research (AACR) Conference on Tumor Immunology and Immunotherapy

September 29, 2020

Beyond Air® Reports Financial Results for First Quarter of Fiscal Year 2021 and Provides Business Update

August 5, 2020

Beyond Air® to Announce Fiscal First Quarter 2021 Financial Results on Thursday, August 6th

July 22, 2020

← Newer news releases

Calls

The 5 newest of 23 calls. Every call is listed under its year.

Decks

The 5 newest of 14 decks. Every deck is listed under its year.